Perhaps no health care company has as many moving parts as Johnson & Johnson (JNJ -0.02%), the sector's most recognizable name that commands a dominant position over seemingly every major medical industry, from consumer health to pharmaceuticals. But even Johnson & Johnson isn't afraid to shake things up when looking for growth, and the company's looking at doing that right now.

For months, talk has waxed and waned over whether J&J would move to sell its Ortho Clinical Diagnostics division. Now that talk is heating up: Sources close to the matter have said that J&J is kicking off the opening moves of the division's sale, which some analysts have said could earn the company up to $5 billion. While the division isn't a major part of J&J, it could be a huge win for a company that has changed dramatically in the past year and boasts a standout diagnostics division of its own: Abbott Labs (ABT -0.24%).

But is Abbott the right suitor for J&J's ortho business from an investor's standpoint? In the video below, Fool contributor Dan Carroll outlines what a potential Johnson & Johnson-Abbott Labs deal for the ortho business could mean for each company and stock -- and what investors should keep an eye out for going forward.